Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...
Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...
1d
Boston Scientific Corp (BSX) reports impressive Q4 2024 results with 22.4% revenue growth and a 26% increase in adjusted EPS, ...
Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...
The company states: “Boston Scientific (BSX) announced data supporting the use of the FARAPULSE Pulsed Field Ablation System* and the WATCHMAN FLX Left Atrial Appendage Closure Device ...
Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO ...
"US pulsed field ablation market revenue exceeds $500m in 2024" was originally created and published by Medical Device ...
Reports Q4 revenue $4.56B, consensus $4.42B. “2024 was one of the best years in the history of Boston Scientific (BSX), fueled by our ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback